NaF PET/CT in prostate cancer

By Kristin Schmiedehausen, MD


Prostate cancer is the second most common cancer in men worldwide.1 Explore the role of PET/CT and the bone-seeking radiopharmaceutical Sodium Fluoride F18 Injection (18F NaF), which together can be an accurate technique for imaging skeletal metastases high-risk patients. Download the white paper below to discover the incremental value of this imaging technique and how this technique might be able to provide additional, valuable information for response management, prognostication, and therapy planning for radionuclide therapy.